| Literature DB >> 34581759 |
Armand M A Linkens1,2, Alfons J H M Houben1,2, Abraham A Kroon1,2, Miranda T Schram1,2, Tos T J M Berendschot3, Carroll A B Webers3, Marleen van Greevenbroek1,2, Ronald M A Henry1,2,4, Bastiaan de Galan1,2, Coen D A Stehouwer1,2, Simone J M P Eussen2,5,6, Casper G Schalkwijk1,2.
Abstract
BACKGROUND: Endogenously formed advanced glycation end products (AGEs) may be important drivers of microvascular dysfunction and the microvascular complications of diabetes. AGEs are also formed in food products, especially during preparation methods involving dry heat.Entities:
Keywords: dietary advanced glycation end products; endothelial function; microvascular function; population-based cohort; ultra-performance liquid chromatography tandem mass spectrometry
Mesh:
Substances:
Year: 2022 PMID: 34581759 PMCID: PMC8827096 DOI: 10.1093/ajcn/nqab302
Source DB: PubMed Journal: Am J Clin Nutr ISSN: 0002-9165 Impact factor: 7.045
FIGURE 1Flowchart of participant selection for the different microvascular outcomes. Please note that missing variables do not necessarily add up because they are not mutually exclusive, e.g., an individual may have missing information on both smoking status and educational level. 1Implausible energy intake: <500 kcal or >3500 kcal for women, <800 or >4000 kcal for men.
Characteristics of those with information on all potential confounders and ≥1 microvascular outcome, stratified by overall dietary AGE intake[1]
| Total sample ( | Dietary AGE quartiles ( | ||||
|---|---|---|---|---|---|
| Characteristics | Q1 ( | Q2 ( | Q3 ( | Q4 ( | |
| Demographics | |||||
| Age, y | 59.9 ± 8.2 | 60.7 ± 8.1 | 60.0 ± 8.4 | 59.6 ± 8.1 | 59.2 ± 8.1 |
| Males | 51.0 | 35.7 | 48.7 | 52.8 | 66.5 |
| Educational level: low/medium/high | 33.5/28.2/38.3 | 38.0/26.1/35.9 | 32.3/27.9/39.9 | 34.0/28.6/37.4 | 29.9/30.2/39.9 |
| Glucose metabolism status: NGM/prediabetes/T2DM/other | 56.6/14.7/27.7/1.0 | 55.3/13.6/30.1/1.0 | 55.9/13.9/29.5/0.8 | 58.0/15.8/25.1/1.1 | 57.1/15.5/26.1/1.3 |
| Lifestyle | |||||
| Smoking: never/former/current | 35.0/52.2/12.8 | 32.9/52.7/14.4 | 36.0/49.9/14.1 | 35.5/52.5/12.0 | 35.8/53.7/10.6 |
| Waist circumference, cm | |||||
| Males | 101.5 ± 12.0 | 103.0 ± 11.8 | 101.6 ± 12.1 | 101.6 ± 11.5 | 100.6 ± 12.5 |
| Females | 89.8 ± 12.8 | 90.1 ± 13.5 | 88.8 ± 11.5 | 89.7 ± 12.5 | 91.2 ± 13.8 |
| BMI, kg/m2 | 27.0 ± 4.5 | 27.1 ± 4.7 | 26.8 ± 4.3 | 27.0 ± 4.4 | 27.2 ± 4.7 |
| Physical activity,[ | 119.3 ± 42.0 | 115.3 ± 43.4 | 116.5 ± 38.7 | 118.5 ± 39.6 | 127.0 ± 45.3 |
| Biological | |||||
| Office systolic BP, mm Hg | 135.0 ± 18.2 | 134.7 ± 18.9 | 133.9 ± 18.2 | 135.5 ± 18.4 | 135.9 ± 17.4 |
| Office diastolic BP, mm Hg | 76.1 ± 9.9 | 75.4 ± 9.9 | 75.3 ± 9.8 | 76.8 ± 9.8 | 77.0 ± 10.0 |
| Antihypertensive medication, yes | 40.3 | 44.3 | 40.2 | 38.9 | 37.9 |
| Total:HDL cholesterol ratio | 3.7 ± 1.2 | 3.6 ± 1.2 | 3.6 ± 1.2 | 3.7 ± 1.1 | 3.8 ± 1.2 |
| Triglycerides, mmol/L | 1.4 ± 0.9 | 1.4 ± 0.8 | 1.4 ± 0.9 | 1.4 ± 0.8 | 1.4 ± 0.9 |
| Lipid-modifying medication, yes | 36.5 | 38.6 | 38.0 | 34.5 | 35.0 |
| Glucose-lowering medication, yes | |||||
| Insulin | 6.8 | 8.0 | 6.9 | 6.5 | 6.0 |
| Oral | 20.2 | 21.2 | 21.8 | 18.8 | 19.1 |
| eGFR,[ | 88.0 ± 15.1 | 86.8 ± 15.4 | 88.3 ± 14.5 | 88.1 ± 14.6 | 88.6 ± 15.1 |
| Retinopathy,[ | 1.6 | 1.0 | 2.0 | 1.5 | 2.1 |
| Medical history of cardiovascular disease,[ | 16.9 | 17.2 | 18.1 | 17.0 | 15.3 |
| Dietary intake | |||||
| Energy intake, kcal/d | 2182 ± 606 | 1620 ± 377 | 1988 ± 348 | 2302 ± 400 | 2819 ± 523 |
| Alcohol, g/d | 8.5 [1.4–18.8] | 7.2 [0.5–18.6] | 8.4 [1.5–17.6] | 8.6 [1.7–17.3] | 9.4 [2.5–20.5] |
| Coffee, g/d | 468.3 ± 296.9 | 418.9 ± 259.0 | 453.3 ± 274.9 | 476.8 ± 300.0 | 524.1 ± 338.5 |
| Tea, g/d | 139.8 [13.0–325.0] | 132.4 [7.5–325.0] | 139.8 [17.5–355.0] | 125.0 [19.4–325.0] | 162.5 [19.4–346.1] |
| Dutch Healthy Diet index[ | 76.0 ± 14.2 | 78.2 ± 14.2 | 77.0 ± 13.8 | 75.4 ± 14.2 | 73.4 ± 14.3 |
| Dietary CML, mg/d | 3.3 ± 1.1 | 2.0 ± 0.4 | 2.8 ± 0.3 | 3.5 ± 0.4 | 4.7 ± 0.9 |
| Dietary CEL, mg/d | 3.0 ± 1.2 | 1.8 ± 0.4 | 2.5 ± 0.3 | 3.1 ± 0.4 | 4.5 ± 1.4 |
| Dietary MG-H1, mg/d | 24.3 ± 8.8 | 15.5 ± 3.1 | 21.0 ± 2.5 | 25.7 ± 3.0 | 35.1 ± 8.8 |
| Retinal microvascular measurements[ | |||||
| Flicker light–induced arteriolar dilation response, % | 3.0 ± 2.8 | 3.0 ± 2.8 | 2.9 ± 2.8 | 3.1 ± 2.8 | 3.2 ± 2.8 |
| Flicker light–induced venular dilation response, % | 3.9 ± 2.2 | 3.9 ± 2.3 | 3.7 ± 2.1 | 3.8 ± 2.2 | 4.0 ± 2.2 |
| CRAE, µm | 142.3 ± 20.3 | 142.8 ± 20.8 | 142.9 ± 20.5 | 142.4 ± 19.7 | 141.2 ± 20.1 |
| CRVE, µm | 214.6 ± 31.4 | 214.3 ± 32.8 | 214.2 ± 30.8 | 215.9 ± 30.5 | 213.7 ± 31.4 |
| Plasma biomarkers of endothelial dysfunction[ | |||||
| sICAM-1, ng/mL | 354.2 ± 99.9 | 362.2 ± 112.9 | 352.9 ± 93.5 | 351.6 ± 90.4 | 350.2 ± 101.0 |
| sVCAM-1, ng/mL | 428.2 ± 101.3 | 429.8 ± 111.8 | 426.0 ± 101.4 | 426.2 ± 90.8 | 430.9 ± 101.3 |
| E-selectin, ng/mL | 118.3 ± 65.2 | 117.9 ± 66.7 | 117.0 ± 71.1 | 119.1 ± 59.9 | 118.3 ± 65.2 |
| von Willebrand factor, % | 132.6 ± 48.4 | 134.3 ± 51.1 | 131.9 ± 47.1 | 132.0 ± 48.4 | 132.4 ± 47.0 |
| Biomarker | 0.0 ± 1.0 | 0.0 ± 1.1 | −0.0 ± 1.0 | −0.0 ± 0.9 | −0.0 ± 1.0 |
| Skin microvascular measurements[ | |||||
| Baseline skin blood flow, PU | 11.1 ± 6.5 | 11.3 ± 7.2 | 10.9 ± 6.1 | 11.1 ± 6.5 | 11.2 ± 6.0 |
| Skin hyperemic response, % | 1124.4 ± 774.1 | 1155.8 ± 788.7 | 1140.6 ± 759.0 | 1129.8 ± 793.0 | 1069.9 ± 752.8 |
| Kidney microvascular measurements | |||||
| Albuminuria,[ | 6.7 [4.0–11.9] | 6.9 [4.2–12.8] | 6.5 [3.8–11.8] | 6.4 [3.9–10.7] | 7.1 [4.3–12.3] |
Values are means ± SDs, medians [IQRs], or percentages. AGE, advanced glycation end product; BP, blood pressure; CEL, Nε-(1-carboxyethyl)lysine; CML, Nε-(carboxymethyl)lysine; CRAE, central retinal arteriolar equivalent; CRVE, central retinal venular equivalent; eGFR, estimated glomerular filtration rate; MG-H1, Nδ-(5-hydro-5-methyl-4-imidazolon-2-yl)-ornithine; NGM, normal glucose metabolism; other, type 1 diabetes or surgery/medicine-induced; PU, perfusion units; Q, quartile; sICAM-1, soluble intracellular adhesion molecule-1; sVCAM-1, soluble vascular adhesion molecule-1; T2DM, type 2 diabetes mellitus.
Physical activity data available in n = 2434.
Markers of microangiopathy, n = 3048.
Modified version of the Dutch Healthy Diet index that does not include alcohol intake.
Static retinal imaging, n = 2736; dynamic retinal imaging, n = 2124 for arteriolar dilation and n = 2158 for venular dilation.
Plasma biomarkers of endothelial dysfunction, n = 3098.
Skin microvascular measurements, n = 1527.
FIGURE 2Multivariate-adjusted associations of dietary AGEs (in SD/d) and microvascular measurements tested with multiple linear regression analysis. βs (95% CIs) indicate the difference in microvascular outcome per 1-SD change in dietary AGE intake. Model 1: adjusted for participant characteristics: age, sex, and glucose metabolism status. Model 2: in addition adjusted for cardiovascular disease risk factors and lifestyle factors: waist circumference, total:HDL cholesterol ratio, triglycerides, smoking habits, use of lipid-lowering medication, office systolic blood pressure, use of antihypertensive medication, caloric intake, educational level, alcohol intake, and the Dutch Healthy Diet index. For albuminuria, model 2 was in addition adjusted for estimated glomerular filtration rate. Sample sizes (n): flicker light–induced arteriolar dilation: 2124; flicker light–induced venular dilation: 2158; central retinal arteriolar and venular equivalents: 2736; plasma biomarker z score: 3098; heat-induced skin hyperemia: 1527; and albuminuria: 3102. AGE, advanced glycation end product; CEL, Nε-(1-carboxyethyl)lysine; CML, Nε-(carboxymethyl)lysine; MG-H1, Nδ-(5-hydro-5-methyl-4-imidazolon-2-yl)-ornithine.